Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

Inclusion Criteria: * Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration within six months of initial study visit, and may have been treated with up to 3 Lucentis® (ranibizumab) or 3 Avastin® (bevacizumab) injections with the last injection administered at least 4 weeks prior to the initial study visit, or is treatment-naïve * Visual acuity of 20/40 to 20/200 in the study eye Exclusion Criteria: * Any other ocular disease that could compromise vision in the study eye * Presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration